| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Conventional drugs: the unmet needs
|
Ardizzone, S.
|
|
2008
|
2 |
1 |
p. 11-12
2 p.
|
artikel
|
| 2 |
Crohn's Disease: Achieving Patients' Benefits Paris, 27th October 2007
|
Ardizzone, S.
|
|
2008
|
2 |
1 |
p. 1-2
2 p.
|
artikel
|
| 3 |
Crohn's disease classification and its clinical usefulness
|
Prantera, C.
|
|
2008
|
2 |
1 |
p. 3-4
2 p.
|
artikel
|
| 4 |
Editorial Board
|
|
|
2008
|
2 |
1 |
p. i-
1 p.
|
artikel
|
| 5 |
How do biological drugs meet treatment goals in anti-TNF naive patients, in patients with anti-TNF failure and in fistulizing patients?
|
Gionchetti, P.
|
|
2008
|
2 |
1 |
p. 13-14
2 p.
|
artikel
|
| 6 |
Improving patients' QoL: how the success of treatment can improve workability
|
Cottone, M.
|
|
2008
|
2 |
1 |
p. 17-18
2 p.
|
artikel
|
| 7 |
New developments in biologics therapy: what about from the medical point of view?
|
Armuzzi, A.
|
|
2008
|
2 |
1 |
p. 25-26
2 p.
|
artikel
|
| 8 |
Opportunistic infections and anti-tumor necrosis factor antagonists in patients with IBD: prevention and diagnosis
|
Rahier, J.F.
|
|
2008
|
2 |
1 |
p. 23-24
2 p.
|
artikel
|
| 9 |
Safety of biologics – which lessons learned?
|
Ghosh, S.
|
|
2008
|
2 |
1 |
p. 19-20
2 p.
|
artikel
|
| 10 |
Safety of biologics: which lessons learned? The rheumatologist's point of view
|
Valesini, G.
|
|
2008
|
2 |
1 |
p. 21-22
2 p.
|
artikel
|
| 11 |
Therapeutic goals in IBD
|
Campieri, M.
|
|
2008
|
2 |
1 |
p. 7-8
2 p.
|
artikel
|
| 12 |
The relevance of mucosal healing
|
Vecchi, M.
|
|
2008
|
2 |
1 |
p. 9-10
2 p.
|
artikel
|
| 13 |
Top down therapy in Crohn's disease
|
Ghosh, S.
|
|
2008
|
2 |
1 |
p. 15-16
2 p.
|
artikel
|
| 14 |
Updates on diagnosis: new tools? How can we measure activity?
|
Pallone, F.
|
|
2008
|
2 |
1 |
p. 5-6
2 p.
|
artikel
|
Tijdschrift beschrijving